Abstract
Anti-Obesity Therapeutics - Pipeline Assessment and Market Forecasts to
2017
Summary
GlobalData, the industry analysis specialist, has released its new report,
“Anti-Obesity - Pipeline Assessment and Market Forecasts to 2017”.
The report is an essential source of information and analysis on the global
Anti-Obesity market. The report identifies the key trends shaping and driving
the global Anti-Obesity market. The report also provides insights on the
prevalent competitive landscape and the emerging players expected to
significantly alter the market positioning of the current market leaders. Most
importantly, the report provides valuable insights on the pipeline products
within the global Anti-Obesitysector. This report is built using data and
information sourced from proprietary databases, primary and secondary research
and in-house analysis by GlobalData’s team of industry experts.
GlobalData has estimated the global anti-obesity market to be valued at $1.1
billion in 2009. It is forecast to grow at a Compound Annual Growth Rate
(CAGR) of 7% for the next seven years to reach $2 billion by 2017. The
increasing patient population and high unmet need in terms of safety and
efficacy will be the primary drivers of this growth. However, safety concerns
with the current anti-obesity drugs and low prescription rates will remain
major challenges to sustain this growth.
Scope
The report provides information on the key drivers and challenges of the
Anti-Obesity market. Its scope includes:
• Annualized global Anti-Obesity market revenues data from 2001 to 2009,
forecast for eight years to 2017.
• Pipeline analysis data providing a split across the different phases,
mechanisms of action being developed and emerging trends. Pipeline candidates
fall under major therapeutic classes such as under appetite suppressants and
calorie/fat absorption inhibitors.
• Analysis of the current and future competition in the global
Anti-Obesity market. Key market player covered are Orexigen Therapeutics, Novo
Nordisk A/S and Takeda Pharmaceutical.
• Insightful review of the key industry drivers, restraints and
challenges. Each trend is independently researched to provide a qualitative
analysis of its implications.
• Key topics covered include strategic competitor assessment, market
characterization, unmet needs and the implications for the Anti-Obesity
therapeutics market.
Reasons to buy
The report will enhance your decision making capability. It will allow you
to:
• Develop and design your in-licensing and out-licensing strategies
through a review of pipeline products and technologies and by identifying the
companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and
driving the global Anti-Obesitymarket.
• Drive revenues by understanding the key trends, innovative products
and technologies, market segments and companies likely to impact the global
Anti-Obesitymarket in future.
• Formulate effective sales and marketing strategies by understanding
the competitive landscape and by analyzing the performance of various
competitors.
• Identify emerging players with potentially strong product portfolios
and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market
categories and segments that present maximum opportunities for consolidations,
investments and strategic partnerships.
• What’s the next big thing in the global Anti-Obesitymarket
landscape? - Identify, understand and capitalize.
Table of Contents
1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 5
2 Anti-Obesity Therapeutics Market: Introduction 6
2.1 Overview 6
2.2 GlobalData Pipeline Report Guidance 7
3 Anti-Obesity Therapeutics Market: Market Characterization 8
3.1 Anti-Obesity Market Size 8
3.2 Anti-Obesity Market Forecast and CAGR 9
3.3 Drivers and Barriers for the Anti-Obesity Market 10
3.3.1 Drivers for the Anti-Obesity Market 10
3.3.2 Barriers for the Anti-Obesity Market 11
3.4 Opportunity and Unmet Need 12
3.5 Key Takeaway 13
4 Anti-Obesity Market: Competitive Assessment 14
4.1 Overview 14
4.2 Strategic Competitor Assessment 14
4.3 Product Profile for the Major Marketed Product in the Anti-Obesity Market
15
4.3.1 Xenical (Orlistat 120mg) and Alli (Orlistat 60mg) 15
4.4 Key Takeaway 16
5 Anti-Obesity Market: Pipeline Assessment 17
5.1 Overview 17
5.2 Strategic Pipeline Assessment 17
5.2.1 Technology Trends Analytic Framework 17
5.3 Anti-Obesity Therapeutics - Promising Drugs under Clinical
Development 18
5.4 Molecule Profile for Promising Drugs under Clinical Development 19
5.4.1 Victoza (liraglutide) 19
5.5 Anti-Obesity Market - Clinical Pipeline by Mechanism of Action
20
5.6 Anti-Obesity Pipeline - Pipeline by Clinical Phases of Development
21
5.6.1 Anti-Obesity Therapeutics - Phase III Clinical Pipeline 21
5.6.2 Anti-Obesity - Phase II Clinical Pipeline 22
5.6.3 Anti-Obesity - Phase I Clinical Pipeline 23
5.6.4 Anti-Obesity - Preclinical Pipeline 24
5.6.5 Anti-Obesity - Discovery Pipeline 25
5.7 Key Takeaway 25
6 Anti-Obesity Market: Implications for Future Market Competition 26
7 Anti-Obesity Market: Future Players in the Anti-Obesity Market 27
7.1 Introduction 27
7.2 Orexigen Therapeutics, Inc 27
7.2.1 Overview 27
7.2.2 Financial Overview 28
7.2.3 Metabolic Disorders Portfolio 28
7.3 Novo Nordisk Pharmaceuticals 28
7.3.1 Overview 28
7.3.2 Business Overview 28
7.3.3 Metabolic Disorders Portfolio 29
7.4 Takeda Pharmaceutical Company Limited 29
7.4.1 Overview 29
7.4.2 Business Overview 30
7.4.3 Metabolic Disorders Portfolio 30
7.5 7TM Pharma 31
7.5.1 Overview 31
7.5.2 Metabolic Disorders Portfolio 31
8 Anti-Obesity Market: Appendix 32
8.1 Definition 32
8.2 Acronyms 32
8.3 Research Methodology 33
8.3.1 Coverage 33
8.3.2 Secondary Research 33
8.3.3 Forecasting 34
8.3.4 Primary Research 37
8.3.5 Expert Panel Validation 37
8.4 Contact Us 37
8.5 Disclaimer 37
8.6 Sources 38
1.1 List of Tables
Table 1: Classification Of Overweight and Obesity By BMI, 2010 6
Table 2: Anti-Obesity Therapeutics, Global, Revenue ($m), 2001-2009
8
Table 3: Anti-Obesity Therapeutics Market, Global, Market Forecasts ($m),
2009-2017 9
Table 4: Anti-Obesity Therapeutics Market, Global, Most Promising
Molecules Under Clinical Development, 2010 18
Table 5: Anti-Obesity Therapeutics Market, Filed and Phase III Clinical
Pipeline, 2010 21
Table 6: Anti-Obesity Therapeutics Market, Phase II Clinical Pipeline, 2010
22
Table 7: Anti-Obesity Therapeutics Market, Phase I Clinical Pipeline, 2010
23
Table 8: Anti-Obesity Therapeutics Market, Preclinical Pipeline, 2010 24
Table 9: Anti-Obesity Therapeutics Market, Discovery Pipeline, 2010 25
Table 10: Orexigen Therapeutics, Metabolic Disorders Pipeline Products, 2010
28
Table 11: Novo Nordisk Pharmaceuticals, Metabolic Disorders Marketed
Products, 2010 29
Table 12: Novo Nordisk Pharmaceuticals, Metabolic Disorders Pipeline
Products, 2010 29
Table 13: Takeda Pharmaceutical, Metabolic Disorders Pipeline Products, 2010
30
Table 14: 7TM Pharma, Metabolic Disorders Pipeline Products, 2010 31
1.2 List of Figures
Figure 1: Anti-Obesity Therapeutics Market, Global, Revenues ($m),
2001-2009 8
Figure 2: Anti-Obesity Therapeutics Market, Global, Market Forecast ($m),
2009-2017 9
Figure 3: Opportunity and Unmet Need in the Anti-Obesity Therapeutics Market,
2010 12
Figure 4: Strategic Competitor Assessment of the Marketed Products in
Anti-Obesity, 2010 14
Figure 5: Technology Trends Analytic Framework of the Anti-Obesity
Therapeutic Pipeline, 2010 17
Figure 6: Technology Trends Analytic Framework of the Anti-Obesity
Therapeutics Pipeline - Description, 2010 18
Figure 7: Anti-Obesity Therapeutics Market, Clinical Pipeline by Mechanism of
Action (%), 2010 20
Figure 8: Anti-Obesity Therapeutics Market, Pipeline by Phase of Clinical
Development (%), 2010 21
Figure 9: Implications for Future Market Competition in the Anti-Obesity
Market, 2010 26
Figure 10: Anti-Obesity Therapeutics Market, Clinical Pipeline by Company,
2010 27
Figure 11: GlobalData Market Forecasting Model 36
